Objectives: Levetiracetam is a broad-spectrum antiepileptic drug (AED) which is currently licensed in the United States and the United Kingdom and Ireland for use as adjunctive treatment of focal-onset seizures and myoclonic seizures or generalized tonic-clonic seizures, occurring as part of generalized epilepsy syndromes. In the United Kingdom and Ireland, it is also licensed as monotherapy treatment for focal-onset seizures. Previous small studies have suggested a low risk for major congenital malformations (MCM) with levetiracetam use in pregnancy.
Pregnancy Registry reported similarly reassuring results, with only 11 MCM in 450 levetiracetam monotherapy exposures (total MCM rate 2.4%). 12 In contrast, the UCB AED Pregnancy Registry reported 12 MCM among 253 levetiracetam monotherapy exposures (MCM rate 4.7%) and 13 MCM in 105 polytherapy exposures (MCM rate 12.4%). 13 Neither the UK Epilepsy and Pregnancy Register nor the North American AED Pregnancy Registry studies replicated results from previous animal and a preliminary human study which had suggested an increase in skeletal abnormalities and low birthweight, respectively. [14] [15] [16] [17] In the UCB registry, 3 of the 10 MCM occurring in children exposed to levetiracetam in the first trimester were skeletal abnormalities.
In contrast to how the effects of AEDs on the developing fetus have previously been reported, the effect of levetiracetam on neurodevelopment has been presented before the risk for MCM has been reported in meaningful numbers of pregnancies. 18 In the joint study by the Liverpool and Manchester Neurodevelopment Group and the UK Epilepsy and Pregnancy Register, only 8% of children exposed to levetiracetam in utero compared to 40% of children exposed to valproate in utero had below average scores for development. The children exposed to levetiracetam in utero had similar developmental scores to the control group, and when compared to valproate, levetiracetam exposure was associated with higher overall developmental quotient scores.
In this article, we present results from the UK and Ireland Epilepsy and Pregnancy Registers in 671 pregnancies exposed to levetiracetam in the first trimester between October 2000 and August 2011.
METHODS The UK Epilepsy and Pregnancy Register is a prospective, observational registration and follow-up study that was set up in 1996 to determine the relative safety of all AEDs taken in pregnancy. The Irish Epilepsy and Pregnancy Register was set up in 2001 and joined the UK Epilepsy and Pregnancy Register in 2007. The 2 studies have the same methodology; both have been approved by national and regional ethical committees and obtain written informed consent from participants. Full details have been published previously. 4 Suitable cases were defined as women with epilepsy who became pregnant while taking levetiracetam, either in monotherapy or polytherapy, and who were referred before the outcome of the pregnancy was known. Most participants register during the first trimester, but registrations are accepted at any time before delivery, as long as the outcome has not been believed to be determined based on the result of any form of prenatal testing. Cases that are referred following antenatal diagnosis of a probable or definite MCM are excluded.
The UK Epilepsy and Pregnancy Register records AED name and dosage at registration only in the majority of cases. If we are informed of dose changes, either during the pregnancy or at the time of follow-up, then the dose recorded is the highest known dose taken during pregnancy. If a second AED is added at any point during the pregnancy, this is recorded as a polytherapy exposure. Recording of smoking and alcohol use, serum AED levels, and analysis of individual physicians' clinical practice (therapeutic drug monitoring or clinical assessment) is not part of the methodology of this study and are not available for this analysis.
An MCM was defined as an abnormality of an essential embryonic structure requiring significant treatment and present at birth or discovered in the first 6 weeks of life, according to the definitions and lists of disorders in the EUROCAT registry. 19 Statistical analysis. Malformation rates were calculated as [total number of live births with a malformation] 1 [total number of pregnancy losses with a malformation] ÷ [total number of live births] 1 [total number of pregnancy losses with a malformation]. Ninety-five percent confidence intervals (CIs) were calculated using the traditional method. Fisher exact test, x 2 test, analysis of variance, and relative risks were used to compare characteristics between groups.
RESULTS Through August 2011, complete outcome data were available for 671 pregnancies. Of these, 304 had been exposed to levetiracetam in monotherapy, and 367 had been exposed to levetiracetam in combination with at least one other AED. Pregnancy outcome details for all exposures are shown in table 1. Two of those on polytherapy combinations had previously had children with MCM (patients 9 and 18). Of all pregnancies exposed to levetiracetam, 93.3% resulted in a live birth and 21 had an MCM (total MCM rate 3.3% [95% CI 2.2%-5.1%]). Details on major malformations are detailed in table 2. Of the women included in table 2, neither of those on levetiracetam monotherapy had a prior personal or family history of MCM.
For monotherapy exposures, there was no significant relationship between mean birthweight or mean gestational age and levetiracetam dose, even when outcomes were compared for those taking doses of less than 1,000 mg daily and those taking 3,000 mg daily or more (p 5 0.43 for mean birthweight; p 5 0.11 for gestational age). The mean levetiracetam dose in pregnancies ending in stillbirths was slightly higher than in those resulting in live births or spontaneous abortions (2,250 mg compared to 1,660 mg and 1,733 mg, respectively). This was not statistically significant (p 5 0.22). The mean levetiracetam dose for those with MCM was 3,000 mg daily, compared to 1,148 mg for those with minor malformations and 1,680 mg for those with normal pregnancy outcomes (p 5 0.09). There was no correlation between MCM occurrence and preconceptual folic acid intake (50% in those with MCM compared to 61% in those without, p 5 1.00).
Information on levetiracetam dose was not available for one woman who had a child with a MCM on levetiracetam polytherapy. This individual was excluded from any analyses regarding dose. Two other women in the polytherapy group who had children with MCM were only taking 250 mg daily of levetiracetam. For polytherapy exposures, there was no obvious relationship between seizure control and the risk of MCM, with 29.6% of women with normal outcomes compared to 10.5% of those with children with MCM having generalized tonic-clonic seizures in the first trimester (p 5 0.11). Polytherapy exposures ending in spontaneous abortions were exposed to higher mean levetiracetam doses than those ending in live births or stillbirths (2,306 mg compared to 1,801 mg and 1,000 mg, respectively). This was statistically significant (p 5 0.02). For polytherapy exposures, there was no correlation between levetiracetam dose and presence of MCM (p 5 0.91). The mean dose of levetiracetam in those with MCM was 1,819 mg compared to 1,784 mg in those with minor malformations and 1,830 mg in those with normal pregnancy outcomes. The MCM rate varied according to the AED given in combination with levetiracetam. The MCM rate for lamotrigine and levetiracetam combinations was 1.8% (95% CI 0.5-6.2), compared to 6.9% (95% CI 1.9-22.0, relative risk 1.41) in those exposed to valproate and levetiracetam and 9.4% (95% CI 4.4-19.0, relative risk 1.91) for carbamazepine and levetiracetam combinations. No MCM were observed in 20 live births to women taking topiramate and levetiracetam polytherapy. For polytherapy exposures, there was no correlation between the occurrence of MCM and preconceptual folic acid intake (55% in those with MCM compared to 52.2% in those without, p 5 0.81).
DISCUSSION
This study confirms previous reports of the low MCM rate with levetiracetam monotherapy exposure during pregnancy. At 0.7% this is lower than previously reported by the North American AED Pregnancy Registry (2.4%) 12 and the UCB Antiepileptic Drug Pregnancy Registry (4.7%), 13 and is similar to MCM rates observed in the nonepilepsy population.
No clear effect of levetiracetam dose on MCM rate was observed in monotherapy or polytherapy exposures. While in the monotherapy group the mean total daily dose of levetiracetam in those resulting in an MCM was nearly double that for those without an MCM, due to the numbers available for study, the results were not statistically significant. In keeping with our previous results we did not find there to be any reduction in mean birthweight for levetiracetam-exposed pregnancies, even at doses over 3,000 mg daily.
MCM rates in those exposed to levetiracetam as part of a polytherapy regimen were significantly higher than for those exposed to levetiracetam in monotherapy. This is in line with previous studies that have consistently shown higher MCM rates for polytherapy compared with monotherapy regimens, both overall and for individual AED regimens. 4, 20 While there are likely a number of reasons for the higher MCM rate in pregnancies exposed to polytherapy regimens, we found the total daily dose of levetiracetam to be similar for the 2 groups. Seizure control was worse in those exposed to levetiracetam as part of a polytherapy regimen and may be implicated in the higher MCM rate for polytherapy exposures.
In keeping with previous studies, 4, 20 we found different risks from different drug combinations that included levetiracetam. While exposure to levetiracetam in combination with valproate or carbamazepine appeared to Table 1 Cumulative outcomes for pregnancies exposed to levetiracetam Registry. 22 The increased MCM rate for levetiracetam and carbamazepine in combination was unexpected and requires replication in other studies. Dose was an important predictor of outcome in the group exposed to levetiracetam as part of a polytherapy regimen, with pregnancies ending in spontaneous abortions being exposed to significantly higher mean daily doses of levetiracetam. Those pregnancies ending in spontaneous abortion were more likely to be in patients on 3 or 4 AEDs (29.2% on 3 drugs and 16.6% on 4 drugs) compared to those resulting in live births or stillbirths (19.2% on 3 drugs and 2.9% on 4 drugs). These patients were also on higher mean total daily doses of other AEDs; for example, for lamotrigine, 500 mg compared to 408 mg, and for topiramate, 800 mg compared to 361 mg, respectively. A similar trend was not seen in the monotherapy group and it is felt that these findings more likely reflect the higher mean drug load in the spontaneous abortion group rather than higher levetiracetam doses.
A weakness of our study is the absence of a control group. While we record data from WWE who are not taking any AEDs at any stage during pregnancy, none of the major epilepsy and pregnancy registers have a control group. 20 Controlling for all potentially important covariables may therefore be impossible.
Systematic recording of all changes in AED dose and recording of serum levels is also not part of our protocol. While the other registers do record AED doses more than once during pregnancy, none records serum levels, and therefore they are unable to estimate adherence to AED regimens and to correlate serum levels with outcome measures. While clearly desirable, it is unlikely that any of the current pregnancy registers, which rely on being as unobtrusive as possible to collect as many cases as possible across large geographical regions, could ever be able to record serum levels. With an ever greater awareness of falling serum levels of AEDs in pregnancy and more active management of AED dosing based on serum measurements in pregnancy, this may change. Another potential weakness of our study is our early follow-up period of 3 months postpartum, compared with other registers. As a result, we may underestimate the risk for certain MCM, in particular cardiac defects, which only become apparent at a later time. The results from other registers will clearly be able to show if this is the case.
These reassuring data on the teratogenic profile of levetiracetam, along with recent publications on neurodevelopment, provide further support for the ongoing widespread use of this drug in WWE. Although there are other issues that need to be resolved with regards to levetiracetam use in pregnancy, including its pharmacokinetics in pregnancy, these results confirm that it is a suitable alternative to valproate in WWE of childbearing age. It should be highlighted, however, that levetiracetam may not be suitable for all WWE. Seizure control is an important factor to consider during pregnancy and some women, particularly those with primary generalized epilepsy syndromes, may require treatment with other AEDs, to include valproate.
